ESTRELLA IMMUNOPHARMA, INC. Gain (Loss) on Investments
ESTRELLA IMMUNOPHARMA, INC. (ESLA) reported Gain (Loss) on Investments of $114.31 thousand for the 3-month period ending 2023-06-30, per its 10-Q filed 2023-08-01.
Discontinued › Income Statement › Other Income
us-gaap:GainLossOnInvestments · last filed 2023-08-01
- ESTRELLA IMMUNOPHARMA, INC. gain (loss) on investments for the quarter ending 2023-06-30 was $114.31K, a 78.11% increase year-over-year.
- ESTRELLA IMMUNOPHARMA, INC. gain (loss) on investments for the quarter ending 2023-03-31 was $105.79K, a 2768.49% increase year-over-year.
- ESTRELLA IMMUNOPHARMA, INC. gain (loss) on investments for the quarter ending 2022-12-31 was $381.89K, a 44461.38% increase year-over-year.
- ESTRELLA IMMUNOPHARMA, INC. gain (loss) on investments for the quarter ending 2022-09-30 was $204.31K, a 35934.04% increase year-over-year.
- ESTRELLA IMMUNOPHARMA, INC. gain (loss) on investments for fiscal 2022 was $654.07K, a 45703.29% increase from fiscal 2021.
- ESTRELLA IMMUNOPHARMA, INC. gain (loss) on investments for fiscal 2021 was $1.43K.
| Period end | Gain (Loss) on Investments 3 month | Gain (Loss) on Investments 6 month | Gain (Loss) on Investments 9 month | Gain (Loss) on Investments 12 month |
|---|---|---|---|---|
| 2023-06-30 | $114.31K 10-Q · filed 2023-08-01 | $220.10K 10-Q · filed 2023-08-01 | $601.99K derived: sum of 3 quarters · filed 2023-08-01 | $806.30K derived: sum of 4 quarters · filed 2023-08-01 |
| 2023-03-31 | $105.79K 10-Q · filed 2023-05-18 | $487.68K derived: sum of 2 quarters · filed 2023-05-18 | $691.99K derived: sum of 3 quarters · filed 2023-05-18 | $756.17K derived: sum of 4 quarters · filed 2023-08-01 |
| 2022-12-31 | $381.89K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $586.20K derived: sum of 2 quarters · filed 2023-03-14 | $650.38K derived: sum of 3 quarters · filed 2023-08-01 | $654.07K 10-K · filed 2023-03-14 |
| 2022-09-30 | $204.31K 10-Q · filed 2022-11-14 | $268.49K derived: sum of 2 quarters · filed 2023-08-01 | $272.18K 10-Q · filed 2022-11-14 | $273.04K derived: sum of 4 quarters · filed 2023-08-01 |
| 2022-06-30 | $64.18K 10-Q · filed 2023-08-01 | $67.87K 10-Q · filed 2023-08-01 | $68.72K derived: sum of 3 quarters · filed 2023-08-01 | $69.29K derived: sum of 4 quarters · filed 2023-08-01 |
| 2022-03-31 | $3.69K 10-Q · filed 2023-05-18 | $4.54K derived: sum of 2 quarters · filed 2023-05-18 | $5.11K derived: sum of 3 quarters · filed 2023-05-18 | $5.12K derived: sum of 4 quarters · filed 2023-05-18 |
| 2021-12-31 | $857.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $1.42K derived: sum of 2 quarters · filed 2023-03-14 | $1.43K derived: sum of 3 quarters · filed 2023-03-14 | $1.43K 10-K · filed 2023-03-14 |
| 2021-09-30 | $567.00 10-Q · filed 2022-11-14 | $571.00 derived: sum of 2 quarters · filed 2022-11-14 | $571.00 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $4.00 10-Q · filed 2022-08-08 | $4.00 10-Q · filed 2022-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |